Potential Impact of COVID-19 on Research report explores the Healthcare Nanotechnology (Nanomedicine) Market for the forecast period, 2020-2026 -…

Healthcare Nanotechnology (Nanomedicine) Marketreport provides in-depth COVID19 impact analysis ofMarket Overview, Product Scope, Market Drivers, Trends, Opportunities,Market Driving Force and Market Risks. It also profile the topmost prime manufacturers (Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith&Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International) are analyzed emphatically by competitive landscape contrast, with respect toPrice, Sales,Capacity, Import, Export, Consumption, Gross, Gross Margin, Revenue and Market Share. Healthcare Nanotechnology (Nanomedicine) industry breakdown data are shown at the regional level, to show the sales, revenue and growth by regions.Healthcare Nanotechnology (Nanomedicine) Market describe Healthcare Nanotechnology (Nanomedicine) Sales Channel,Distributors, Customers, Research Findings and Conclusion, Appendix and Data Source.

Key Target Audience of Healthcare Nanotechnology (Nanomedicine) Market:Manufacturers of Healthcare Nanotechnology (Nanomedicine), Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Healthcare Nanotechnology (Nanomedicine) market.

Get Free Sample PDF (including full TOC, Tables and Figures)of Healthcare Nanotechnology (Nanomedicine)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2041239

In-Depth Qualitative Analyses Include Identification and Investigation Of The Following Aspects:Healthcare Nanotechnology (Nanomedicine) Market Structure, Growth Drivers, Restraints and Challenges, Emerging Product Trends & Market Opportunities, Porters Fiver Forces.

Summary of Healthcare Nanotechnology (Nanomedicine) Market:It is defined as the study of controlling, manipulating and creating systems based on their atomic or molecular specifications. As stated by the US National Science and Technology Council, the essence of nanotechnology is the ability to manipulate matters at atomic, molecular and supra-molecular levels for creation of newer structures and devices. Generally, this science deals with structures sized between 1 to 100 nanometer (nm) in at least one dimension and involves in modulation and fabrication of nanomaterials and nanodevices.

Nanotechnology is becoming a crucial driving force behind innovation in medicine and healthcare, with a range of advances including nanoscale therapeutics, biosensors, implantable devices, drug delivery systems, and imaging technologies.

The classification of Healthcare Nanotechnology includes Nanomedicine, Nano Medical Devices, Nano Diagnosis and Other product. And the sales proportion of Nanomedicine in 2017 is about 86.5%, and the proportion is in increasing trend from 2013 to 2017.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Healthcare Nanotechnology (Nanomedicine) market foreach application, including-

Anticancer CNS Product Anti-infective Other

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type, primarily split into-

Nanomedicine Nano Medical Devices Nano Diagnosis Other

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2041239

Important Healthcare Nanotechnology (Nanomedicine) Market Data Available In This Report:

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

Read more:

Potential Impact of COVID-19 on Research report explores the Healthcare Nanotechnology (Nanomedicine) Market for the forecast period, 2020-2026 -...

New nanomedicines for mRNA therapeutics in breast cancer and heart failure – Mirage News

TAU researcher Prof. Dan Peer, from the school of Molecular Cell Biology and Biotechnology, is one of 11 partners in the international project EXPERT that has been awarded a total of 14.9 million EUR from the EU Horizon 2020. The project is working to find efficient ways to deliver protein coding mRNA by using various nanoparticles for the treatment of breast cancer and myocardial infarction, which are two of the most pressing health challenges in European society today.

Prof. Dan Peer, Director, Laboratory of Precision NanoMedicine, School of Molecular Cell Biology and Biotechnology, George S. Wise Faculty of Life Sciences and Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University Center for Nanoscience and Nanotechnology and Tel Aviv University Cancer Biology Research Center.

It is about developing mRNA therapy for the treatment of breast cancer. Much of it involves testing different methods to improve the delivery of mRNA to cells in vivo. These methods are fundamentally based either on lipid nanoparticles (LNPs), biological nanoparticles called exosomes, or cell penetrating peptides (CPPs). In addition to this, we intend to analyze what these nanoparticles bind to in biological fluids in order to better understand what drives uptake in specific cells types.

Our lab was the first to show systemic, cell specific delivery of mRNA molecules that express therapeutic proteins in designated cells. We will further develop our ASSET platform for cell specific targeting of lipid nanoparticles to achieve improved delivery of therapeutic mRNAs and optimize formulations that enable systemic administration in different preclinical models. Part of the work will also consist of understanding how nanoparticle surfaces bind to host factors in blood and how this can affect the uptake of nanoparticles.

We will now see how these delivery methods work side by side in cell culture and animal models. The hope is then to be able to deliver an mRNA cocktail with one of the aforementioned vectors for the treatment of triple-negative breast cancer. In parallel, these vectors will also be evaluated for delivery of VEGF mRNA in the treatment of myocardial infarction.

Follow this link:

New nanomedicines for mRNA therapeutics in breast cancer and heart failure - Mirage News

New Comprehensive Report on Antibacterial Nano Coatings Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like Nanogate AG,…

Latest Research Report: Antibacterial Nano Coatings industry

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Antibacterial Nano Coatings Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/86745

Antibacterial Nano Coatings Market competition by top manufacturers as follow: , Buhler Partec GmbH, 3M, Bio-Gate AG, Toto, Smith and Nephew, Eikos, Cima NanoTech, Integran Technologies, Nanogate AG, Nanovere Technologies, Nanophase Technologies

The risingtechnology in Antibacterial Nano Coatingsmarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.

The Type Coverage in the Market are: Chemical Vapor Deposition (CVD)Physical Vapor Deposition (PVD)Atomic Layer Deposition (ALD)Others

Market Segment by Applications, covers:MedicineFood PackagingWater TreatmentCoating

The research report summarizes companies from different industries. This Antibacterial Nano Coatings Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.

Antibacterial Nano Coatings is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.

To get this report at a profitable rate.: https://reportsinsights.com/discount/86745

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Antibacterial-Nano-Coatings-Market-86745

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Continue reading here:

New Comprehensive Report on Antibacterial Nano Coatings Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like Nanogate AG,...

Nanomedicine Market with Emerging Trends, Global Scope and Demand 2020 to 2026 – The Canton Independent Sentinel

The Global Nanomedicine Market Report contains essential details of the industry, intended to help the customers identify the optimum approaches to get ahead in the market and make well-informed decisions. An extensive overview of the global sector included in the report examines vital market information to forecast the growth of the market in the forecast duration. The CAGR of the market for the coming years to 2026 has been estimated based on a detailed assessment of the market with authentic and relevant information pertaining to the different segments of the sector. The driving and restraining factors prevailing in the industry have been studied to predict their impact on the growth of the Nanomedicine market in the coming years.

This is the only report that is inclusive of the current effect of the coronavirus on the market and its future trends. The coronavirus has widely impacted the world economy, and its aftereffects are elucidated in detail in the report for the Nanomedicine market.

The sample of the report can be availed by [emailprotected] https://www.reportsanddata.com/sample-enquiry-form/1048

It provides an elaborate breakdown of critical market statistics, market estimation, and profiles of leading players operating in the global Nanomedicine industry.

In market segmentation by manufacturers, the report covers the following companies-

Arrowhead Pharmaceuticals, Inc., Nanospectra Biosciences, Inc., AMAG Pharmaceuticals, Bio-Gate AG, Celgene and Johnson & Johnson

Nanomedicine product types, applications, geographies, and end-user industries are the key market segments that are comprised in this study. The report speculates the prospective growth of the different market segments by studying the current market standing, performance, demand, production, sales, and growth prospects existing in the market.

Get a discount on your copy of the [emailprotected] https://www.reportsanddata.com/discount-enquiry-form/1048

Major highlights of the global Nanomedicine market report:

The report depicts all the analytical details in a well-structured manner, for example, in the statistics, graphs, tables, through which users can more easily grasp detailing. Moreover, it discusses accurate forecasts and gives a detailed research methodology.

The global Nanomedicine market report answers some important questions for you:

Read the full Research Report along with a table of contents, facts and figures, charts, graphs, [emailprotected] https://www.reportsanddata.com/report-detail/nanomedicine-market

To summarize, the global Nanomedicine market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

David is an Experience Business writer who regularly contribute to the blog, He specializes in manufacturing news

Read the rest here:

Nanomedicine Market with Emerging Trends, Global Scope and Demand 2020 to 2026 - The Canton Independent Sentinel

3D Printed Medicine Uses Fish Gelatin to Deliver Cancer Treatment – 3DPrint.com

Japanese researchers Jin Liu, Tatsuaki Tagami, and Tetsuya Ozeki have completed a recent study in nanomedicine, releasing their findings in Fabrication of 3D Printed Fish-Gelatin-Based Polymer Hydrogel Patches for Local Delivery of PEGylated Liposomal Doxorubicin. Experimenting with a new drug delivery system, the authors report on new potential for patient-specific cancer treatment.

The study of materials science continues to expand in a wide range of applications; however, bioprinting is one of the most exciting techniques as tissue engineering is expected to lead to the fabrication of human organs in the next decade or so. Such research has also proven that bioprinting may yield much more powerful drug delivery whether in using hybrid systems, multi-drug delivery systems, or improved scaffolds.

Here, the materials chosen for drug delivery are more unique as the researchers combined printer ink with semi-synthesized fish gelatin methacryloyl (F-GelMA)a cold fish gelatin derivative.

In providing aggressive cancer treatment to patients, the use of doxorubicin (DOX) is common as an anti-carcinogen for the treatment of the following diseases:

DOX may also cause serious cardiotoxicity, however, despite its use as a broad-spectrum drug. As a solution, PEGylated liposomal DOX, Doxilhas been in use for treatment of cancer with much lower cardiotoxity. The nanomedicine has also been approved by the FDA, and is used for targeting local tumors; for instance, this type of drug delivery system could be suitable for treating a brain tumor.

PEGylating liposomes can prolong their circulation time in blood, resulting in their passive accumulation in cancer tissue, called the enhanced permeability and retention effect, state the authors.

Using a 3D bioprinter, the authors developed liposomal patches to be directly implanted into cancerous cells.

(a) Synthesis of fish gelatin methacryloyl (F-GelMA). (b) Hybrid gel of cross-linked F-GelMA and carboxymethyl cellulose sodium (CMC) containing PEGylated liposome. The reaction scheme was prepared in previous studies

We used a hydrogel containing semi-synthetic fish-gelatin polymer (fish gelatin methacryloyl, F-GelMA) to entrap DOX-loaded PEGylated liposomes. Fish gelatin is inexpensive and faces few personal or religious restrictions, stated the authors.

Fish gelatin has not been used widely in bioprinting, however, due to low viscosity and rapid polymerization. To solve that problem, the authors created a bioink composite with elevated viscosity.

Viscous properties of drug formulations used as printer inks. (a) The appearance of F-GelMA hydrogels containing different concentrations of CMC. (b) The viscosity profiles of F-GelMA hydrogels containing different concentrations of CMC. The data represent the mean SD (n = 3).

And while hydrogels are generally attractive for use due to their ability to swell, for this study, the researchers fabricated a variety of different materialswith the combination of 10% F-GelMA and 7% carboxymethyl cellulose sodium (a thickening agent) showing the highest swelling ratio.

Swelling properties of hydrogels after photopolymerization. (a) Swelling ratio of different concentrations of F-GelMA. (b) Swelling ratio of mixed hydrogel (10% F-GelMA with different concentrations of CMC). The data represent the mean SD (n = 3).

Design of the different 3D geometries: (a) cylinder, (b) torus, and (c) gridlines.

Patches were printed in three different sample shapes, using a CELLINK bioprinter syringe as the authors tested drug release potential in vivo. Realizing that surface area, crosslinks density, temperature, and shaker speed would play a role, the team relied on a larger surface volume for more rapid release of drugs.

Printing conditions of patches.

While experimenting with the torus, gridline, and cylindrical sample patches, the researchers observed gridline-style patches as offering the greatest potential for sustained release.

Drug release profiles of liposomal doxorubicin (DOX). (a) Influence of shape on drug release. The UV exposure time was set to 1 min. (b) Influence of UV exposure time on drug release. The gridline object was used for this experiment. The data represent the mean SD (n = 3).

These results indicate that CMC is useful for adjusting the properties of printer ink and is a useful and safe pharmaceutical excipient in drug formulations. We also showed that drug release from 3D-printed patches was dependent on the patch shapes and UV exposure time, and that drug release can be controlled. Taken together, the present results provide useful information for the preparation of 3D printed objects containing liposomes and other nanoparticle-based nanomedicines, concluded the authors.

Continued here:

3D Printed Medicine Uses Fish Gelatin to Deliver Cancer Treatment - 3DPrint.com

INBRAIN Neuroelectronics receives funding to push forward the development of graphene-based implants for brain disorders – Graphene-Info

INBRAIN Neuroelectronics, a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2), the Barcelona Institute of Science and Technology (BIST) and ICREA, has received funding from Sabadell Asabys and Alta Life Sciences, as well as ICF and Finaves, which will allow the company to speed up the development of novel graphene-based implants to optimize the treatment of brain disorders, such as Parkinsons and epilepsy.

INBRAIN Neuroelectronics was established in 2019 with the mission of developing brain-implants based on graphene technology for application in patients with epilepsy, Parkinsons, and other neuronal diseases. These smart devices, built around an innovative graphene electrode, will decode with high certainty neural signals from the brain and produce a therapeutic response adapted to the clinical condition of the specific patient.

The company is designing the least invasive and smartest neural interface that, powered by artificial intelligence and the use of Big Data, will have the ability to read and modulate brain activity, detect specific biomarkers, and trigger adaptive responses to deliver optimal results in personalised neurological therapies. So far, the technology has been validated in in-vitro and in-vivo biocompatibility and toxicity tests and has been successfully used to complete studies on small animals. Recently, INBRAIN began tests on large animals with the aim of ensuring that these graphene devices are safe as well as superior to current solutions based on metals such as platinum and iridium. The company also plans to start human studies soon.

INBRAIN was founded, among others, by ICREA Prof. Jose Garrido, leader of the ICN2 Advanced Electronic Materials and Devices Group, Prof. Kostas Kostarelos, leader of the ICN2 Nanomedicine Group, and Dr. Anton Guimer, a researcher at the Spanish National Centre of Microelectronics (IMB-CNM).

Within the framework of the Graphene Flagship, which is a European macroproject, explains Prof. Garrido, we were able to develop this novel graphene-based technology that will allow measuring and stimulating neuronal activity in the brain with a resolution much higher than that of current commercial technologies.

Throughout 2019, the incorporation of INBRAIN was a priority project for the ICN2 Business and Innovation Department, which coordinated the technology transfer process and successfully orchestrated the licensing of this high-potential technology.

Minimally invasive electronic therapies represent a revolutionary alternative with less potential cost for health systems, comments Carolina Aguilar, CEO of INBRAIN and a former global executive at Medtronic in the field of neuro-stimulation. In our case, the application of new 2D materials such as graphene represents a real opportunity to understand the brain workings in order to optimise and personalize the treatment.

See the rest here:

INBRAIN Neuroelectronics receives funding to push forward the development of graphene-based implants for brain disorders - Graphene-Info

Nanotechnology for Healthcare Market Global Competitions and Business Outlook 2020 to 2026 – News Collective

The report discusses many vital industry facets that influence global Nanotechnology for Healthcare Market industry acutely which includes extensive study of competitive edge, latest advancements, region-wise industry environment, contemporary market and emerging latest trends, leading market contenders, and current tendency of the consumers. The report also oversees market size, market share, growth rate, revenue, and CAGR reported previously along with its forecast estimation.

(Special Offer: Available up-to 20% Discount For a Limited Time Only)

Get a Free Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/06122088071/global-nanotechnology-for-healthcare-market-size-status-and-forecast-2020-2026/inquiry?source=newscollective&mode=90

Global Nanotechnology for Healthcare Market Analysis Report includesTop Companies:Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International along with their company profile, growth aspects, opportunities, and threats to the market development. This report presents the industry analysis for the forecast timescale. An up-to-date industry details related to industry events, import/export scenario, market share is covered in this report.

Global Nanotechnology for Healthcare Market Split by Product Type and Applications:

This report segments the global Nanotechnology for Healthcare market on the basis ofTypesare:

Nanomedicine

Nano Medical Devices

Nano Diagnosis

Other

On the basis of Application, the Global Nanotechnology for Healthcare market is segmented into:

Anticancer

CNS Product

Anti-infective

Other

Regional Analysis For Nanotechnology for Healthcare Market:

For comprehensive understanding of market dynamics, the global Nanotechnology for Healthcare market is analyzed across key geographies namely: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

This study mainly helps to understand which Nanotechnology for Healthcare market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize Growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/Nanotechnology for Healthcare players in the market.

Ask For Discount

https://www.marketinsightsreports.com/reports/06122088071/global-nanotechnology-for-healthcare-market-size-status-and-forecast-2020-2026/discount?source=newscollective&mode=90

Influence of the Nanotechnology for Healthcare Market Report:

-Comprehensive assessment of all opportunities and risk in the Nanotechnology for Healthcare market.

-Nanotechnology for Healthcare market recent innovations and major events.

-Detailed study of business strategies for growth of the Nanotechnology for Healthcare market-leading players.

-Conclusive study about the growth plot of Nanotechnology for Healthcare market for forthcoming years.

-In-depth understanding of Nanotechnology for Healthcare market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Nanotechnology for Healthcare market.

Finally, Nanotechnology for Healthcare Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Browse The Full Reportdescription and table of contents.

https://www.marketinsightsreports.com/reports/06122088071/global-nanotechnology-for-healthcare-market-size-status-and-forecast-2020-2026?mode=90

Research Methodology:

Nanotechnology for Healthcare Marketreport includes the estimation of market size for value (million USD) and volume (M Sqm). Both Top-down and bottom-up approaches have been used to estimate and validate the market size of Nanotechnology for Healthcare Market, to estimate the size of various other dependent submarkets in the overall market.

Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

We also offer customization on reports based on specific client requirement:

1- Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis ofany 5 key market players.

3-Free40 analyst hoursto cover any other data points.

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

View post:

Nanotechnology for Healthcare Market Global Competitions and Business Outlook 2020 to 2026 - News Collective

Combination Therapy of Lung Cancer Using Layer-by-Layer Cisplatin Prod | DDDT – Dove Medical Press

Yuan Hong,1 Shaomin Che,2 Beina Hui,2 Xiaoli Wang,2 Xiaozhi Zhang,2 Hailin Ma2

1Department of Medical Imaging, The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, Peoples Republic of China; 2Department of Oncology Radiotherapy, The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, Peoples Republic of China

Correspondence: Hailin MaDepartment of Oncology Radiotherapy, The First Affiliated Hospital of Xian Jiaotong University, No. 277 Yanta Xi Road, Xian, Shaanxi 710061, Peoples Republic of ChinaEmail mahlxjtu@sohu.com

Purpose: Lung cancer remains the leading cancer-associated deaths worldwide. Cisplatin (CDDP) was used in combination with curcumin (CUR) for the treatment of non-small cell lung cancer. The aim of this study was to prepare and characterize CDDP prodrug and CUR co-encapsulated layer-by-layer nanoparticles (CDDP-PLGA/CUR LBL NPs) to induce cooperative response, maximize the therapeutic effect, overcome drug resistance, and reduce adverse side effects.Methods: CDDP prodrug (CDDP-PLGA) was synthesized. CDDP-PLGA/CUR LBL NPs were constructed and their physicochemical properties were investigated by particle-size analysis, zeta potential measurement, drug loading, drug entrapment efficiency, and in vitro drug release behavior. In vitro cytotoxicity against human lung adenocarcinoma cell line (A549 cells) was investigated, and in vivo anti-tumor efficiency of CDDP-PLGA/CUR LBL NPs was evaluated on mice bearing A549 cell xenografts.Results: CDDP-PLGA/CUR LBL NPs have a size of 179.6 6.7 nm, a zeta potential value of 29.9 3.2 mV, high drug entrapment efficiency of 85.6 3.9% (CDDP) and 82.1 2.8% (CUR). The drug release of LBL NPs exhibited a sustained behavior, which made it an ideal vehicle for drug delivery. Furthermore, CDDP-PLGA/CUR LBL NPs could significantly enhance in vitro cytotoxicity and in vivo antitumor effect against A549 cells and lung cancer animal model compared to the single drug-loaded LBL NPs and free drug groups.Conclusion: CDDP-PLGA/CUR LBL NPs were reported for the first time in the combination therapy of lung cancer. The results demonstrated that the CDDP-PLGA/CUR LBL NPs might be a novel promising system for the synergetic treatment of lung carcinoma.

Keywords: lung cancer, combination therapy, layer-by-layer, cisplatin prodrug, curcumin

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post:

Combination Therapy of Lung Cancer Using Layer-by-Layer Cisplatin Prod | DDDT - Dove Medical Press

Medical Biomimetics – Market Research | Recent Trends and Growth Forecast 2025 – CueReport

A detailed overview of Medical Biomimetics market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of Medical Biomimetics market in conjunction with the geographical landscape, demand spectrum, remuneration scale, and growth graph of this vertical have also been included in this report.

Increasing rate of organ failure coupled with growing geriatric population base will act as growth impact rendering factors for medical biomimetics market during the forecast timeframe. As per the U.S. Census Bureau?s 2017 National Population Projections, there will be nearly 78 million people aged more than 65 years, while 76.7 million under 18 years of age in the U.S. by 2035, thereby escalating demand for biomimetics products in coming future.

Medical Biomimetics Market will reach over USD 35 billion by 2025; as per a new research report.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/3743

Orthopedic product segment accounted for more than 30% market share in 2018 and is estimated to witness significant growth during the forecast period owing to growing demand for orthopedic prosthesis and implants. For instance, increasing number of accidents and injuries have escalated the demand for prosthetic limbs. Technological advancements including development of augment bone graft should positively impact segmental growth.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/3743

High adoption of western culture, unhealthy diet and physical inactivity has led to rising incidence of cardiovascular diseases, resulting in increased demand for biomimetic cardiovascular products. Numerous applications of biomimetics in healthcare industry including fields such as dentistry, orthopedics, cardiovascular, and ophthalmology should stimulate business growth during the analysis period.

Application segment of medical biomimetics market includes plastic surgery, wound healing, tissue engineering, drug delivery and others including nanomedicine, drug discovery, enzymatic modification and medical engineering. Plastic surgery application segment will witness 6.3% CAGR over the coming years due to wide application of biomimetics in plastic surgery for scaffold formation. It is also used in craniofacial surgery for restoration of facial aesthetics, function and form.

Increasing R&D activities pertaining to development of innovative biomimetic products along with advancements in nanotechnology, tissue engineering utilizing biomimetics technology should positively impact industry expansion. However, high capital investment in R&D along with stringent regulations will hinder industry growth during the forecast timeframe.

Germany medical biomimetics market dominated European region in 2018 and is anticipated to grow at 5.8% during the forecast period. High technological adoption, rising geriatric population prone to suffer from organ failure and increasing incidence of ophthalmology, orthopedic and cardiovascular disorders in the country are driving factors for Germany medical biomimetics market.

Saudi Arabia medical biomimetics market will witness 5.2% CAGR during the forecast timeframe. Growing demand and adoption of cosmetic surgical procedures among women, technological advancements and rising awareness should drive Saudi Arabia medical biomimetics industry during the analysis period. Rising incidence of coronary heart disease coupled with growing uptake of unhealthy habits such as alcohol consumption and tobacco smoking will augment demand for biomimetic products in the region.

Few notable companies operating in global medical biomimetics market are

Abbott, Veryan Medical, Biomimetics Technologies, Avinent, BioHorizons, Applied Biomimetic, and BioHorizons IPH. Industry players are collaborating with universities and other research institutes to strengthen development of innovative biomimetic products. In December 2018, University of Minnesota Technology Commercialization announced launch of Vascudyne Inc., a start-up company focusing on development of biologically engineered tissue offering regenerative capacity for therapeutic and medical applications.

Major Highlights from Table of contents are listed below for quick lookup into Medical Biomimetics Market report

Chapter 1. Competitive Landscape

Chapter 2. Company Profiles

Chapter 3. Methodology & Scope

Chapter 4. Executive Summary

Chapter 5. Medical Biomimetics industryInsights

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/3743

Read more here:

Medical Biomimetics - Market Research | Recent Trends and Growth Forecast 2025 - CueReport

‘Laser tweezers’ in nano lab used in search for drug to prevent COVID-19 replication – The Province

By Nicole Bergot

A drug can prevent the virus responsible for the COVID-19 pandemic from replicating once inside an infected host, say researchers at the University of Alberta now searching for that magic bullet.

We aim to identify drugs that can be tested for effectiveness and safety in future trials, said Michael Woodside, a professor in the department of physics, using $370,700 in emergency funding from the Canadian Institutes of Health Research (CIHR) to find the elusive drug.

The plan is to screen first for drugs that are already approved for human use that could be repurposed to treat COVID-19 more quickly before broadening the search to potential drugs that are not currently approved.

Woodside explains that the genome of the novel coronavirus is made up of ribonucleic acid (RNA), not DNA so once inside an infected host, the virus inserts its RNA genome into the cell causing the creation of proteins the virus needs to replicate. And for all of this to occur, the novel coronavirus uses a process called programmed ribosomal frameshibing (PRF), a topic that Woodside, as a biophysicist, and his lab have been studying for years.

Researchers using laser tweezers to mimic what happens inside an infected cell were able to identify the mechanism through which PRF is triggered and now they can find molecular compounds to stop it from happening.

Most efforts to find drugs look for compounds that target the viral proteins directly, explains Woodside. Whats different about our approach is that we are targeting the virus through its RNA, rather than the proteins.

Woodside, inside the National Research Council of Canadas Nanotechnology Research Centre right here in Edmonton, is working closely with grad students, American counterparts, and Jack Tuszynski, a biophysics professor also in the department of physics, currently on secondment to the department of oncology in the faculty of medicine and dentistry.

Interdisciplinary research and scientific collaborations are essential to stopping the COVID-19 pandemic, said Woodside. Solutions have to engage expertise and approaches across a wide range of areas to understand the biophysics of the viral molecules, the biology of virus replication, the chemistry of drugs and their interactions with targets, the response of the immune system, the symptoms and epidemiology of the disease, and the response of patients to treatments.

Building and validating a model of the viral RNA for drug screening will occur over the next few months, with screening to identify approved drugs to follow before any potential candidates move toward preclinical tests.

Go here to read the rest:

'Laser tweezers' in nano lab used in search for drug to prevent COVID-19 replication - The Province

Missouri Indian American Professor Develops Disinfecting Tunnel to Kill Viral Infections Using Silver Nano-particles – India West

An Indian American professor has developed the technology behind the Nanolife Disinfectant Tunnel, which successfully uses silver nano-particles to kill off viral infections.

Kattesh Katti, professor of radiology and director of the Institute of Green Nanotechnology at the University of Missouri in Columbia, Mo., told India-West the technology has been tested successfully on COVID-related viruses. Currently, the 8-foot-long tunnel has been deployed at three locations in Chennai, including the Tirumala Tirupati Temple, where thousands of devotees worship each day.

Indias Prime Minister Narendra Modi has placed an order for more tunnels, according to Katti, which are distributed in India through the company Nanolife.

Katti discovered the effectiveness of silver nano-particles in killing off viruses 20 years ago, and commercialized the technology via a hand sanitizer that uses no alcohol or chemicals. The technology was also being used as a cleaning agent in Indian hospitals, he said.

Then the COVID-19 pandemic hit; Katti and the team at Nanolife re-purposed their technology to address the global crisis, which has killed more than 214,000 people around the world, and infected more than three million people.

India, currently on a nationwide quarantine ordered by Modi in March, has a relatively low rate of infection and death from COVID-19: the country had reported 937 deaths and approximately 30,000 infections as of April 28.

But the countrys overcrowded conditions which make required social distancing difficult could drastically raise the number of deaths from the virus, predict Indian epidemiologists.

A country like India really needs more resources, Katti told India-West. The very high population density makes the pandemic significantly more dangerous, he said.

Unlike other disinfecting tunnels currently used in India and some other countries, Nanolifes disinfectant tunnel uses no harmful chemicals, which could be toxic. The technology is based simply on silver nano-particles, water and a proprietary herb that keeps the particles intact, said Katti, adding that the product is used in very low concentrations in the tunnels.

Prof. Jagat Ram of the Postgraduate Institute of Medical Education and Research, Chandigarh, and Prof. JS Thakur, chairman, Covid-19 Prevention Committee at PGI, have questioned the efficacy of disinfecting tunnels, stating that they provide people with a false sense of security. But the tunnels to which they were referring to use sodium hypochlorite, which is known to have several serious side effects. Nanolifes tunnels have no side effects, according to Katti.

The Government of India has banned the export of COVID-related technology, citing the huge need within the country for such products. Thus, for the moment, the Nanolife Disinfectant Tunnel is limited to deployment in India, but Katti is aiming to eventually bring the device to the U.S.

The Dharwad native said he envisions the Nanolife Disinfectant Tunnel in front of railway stations, airports, office buildings, and other large gathering places. Demand far outweighs production capability at the moment, he told India-West.

According to his bio, green nanotechnology is at the focal point of Katti's approach to pursuing research in nanotechnology and molecular medicine as he strongly believes in the total elimination of toxic chemicals in the production of engineered nanoparticles.

He uses phytochemicals occurring naturally within plants and herbs for nano constructs in a variety of applications.

See the original post here:

Missouri Indian American Professor Develops Disinfecting Tunnel to Kill Viral Infections Using Silver Nano-particles - India West

Triple Negative Breast Cancer Treatment Market to Grow at Stellar CAGR Double In% During the Forecast Period 2026 – Cole of Duty

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

Report Highlights:

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/14305

Company Profiles

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/14305

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs.

Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare. The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care.

A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer.

Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market. Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities.

This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/14305

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy. Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market.

Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Link:

Triple Negative Breast Cancer Treatment Market to Grow at Stellar CAGR Double In% During the Forecast Period 2026 - Cole of Duty

PDF | What Is The Impact Of COVID 19 On Nano-Silicon Dioxide Market? | Eon Market Research Analysis Report 2020 – MR Invasion

Eon Market Research has provided a complete research study on Global Nano-Silicon Dioxide Market which portrays the current market situation along with the past, present, and futuristic aspects in the Nano-Silicon Dioxide market. In the beginning, the report represents elemental information about the Nano-Silicon Dioxide industry, which contains the basic overview product types & applications of product. This report also covers the growth opportunities and the limiting factors of the Nano-Silicon Dioxide market.

For a better understanding, the Nano-Silicon Dioxide market study is organized as a chapter. The report helps to see who are the main key players, what benefits do they expect? Define the key strength and success factor of Nano-Silicon Dioxide. The global industry Nano-Silicon Dioxide also offers the current market scenario based on the status of the report, market maturity, as well as the Nano-Silicon Dioxide past and future market trends that will drive industry development Nano-Silicon Dioxide.

Download FREE Sample Report of Nano-Silicon Dioxide Market Report for Better Understanding: https://www.eonmarketresearch.com/sample/64203

[Note: Our free sample report contains a brief introduction to the synopsis, table of contents, list of tables and figures, competitive landscape and geographic segmentation, innovation and future developments based on the methodology of the investigation]

The detailed research report on Nano-Silicon Dioxide Market offers an overview of the top key players contributing to the industrial market and offers a complete overview of the new market records. The main manufacturers included in this report are Dupont, Cabot, Evonik Industries, AkzoNobel, Dow Corning, Bee Chems, NanoPore Incorporated, NanoAmor, Fuso Chemical, Wacker Chemie. This report begins with a market point of view and offers markets a significant investment and the description of world trade Nano-Silicon Dioxide. The summary part of the report consists of Nano-Silicon Dioxide market dynamics covering market growth factors, control elements, occasions, and Nano-Silicon Dioxide current trends along with the analysis of the preference chain and detailed study of prices.

Buy This Premium Report @https://www.eonmarketresearch.com/buy/64203

By Types:

Physical ManufacturingChemical Manufacturing

By Applications:

CatalystMedicineNew MaterialOther

Region Coverage:

1. North America (USA, Canada, Mexico).

2. Europe (United Kingdom, France, Germany, Spain, Italy and rest of Europe).

3. Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific).

4. Latin America (Brazil, Argentina, Colombia and the rest of L.A.).

5. Middle East and Africa (Turkey, GCC, United Arab Emirates and South Africa Rest of the Middle East).

Do Inquiry Before Purchasing Report Here and Ask For Discount @ https://www.eonmarketresearch.com/enquiry/64203

The Market Research Objectives Nano-Silicon Dioxide Are:

1. Market analysis Nano-Silicon Dioxide (historical, current and forecast data) to analyze the growth ratio and market size Nano-Silicon Dioxide.

2. Nano-Silicon Dioxide Market risk, market opportunities, growth forces and business limiting factors.

3. It provides a transparent research plan on the Nano-Silicon Dioxide existing competitors along with the new ones.

About Us:

Eon Market Research is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialists with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever-new fun research methods developed by our team.

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email: sales@eonmarketresearch.com

The rest is here:

PDF | What Is The Impact Of COVID 19 On Nano-Silicon Dioxide Market? | Eon Market Research Analysis Report 2020 - MR Invasion

Nano Medicine: Meaning, Advantages and Disadvantages

In this article we will discuss about Nano Medicine:- 1. Meaning of Nano Medicine 2. Advantages of Nano Medicine 3. Disadvantages.

The application of nanotechnology in medicine is often referred to as Nano medicine. Nano medicine is the preservation and improvement of human health using molecular tools and molecular knowledge of the human body. It covers areas such as nanoparticle drug delivery and possible future applications of molecular nanotechnology (MNT) and Nano-vaccinology.

The human body is comprised of molecules. Hence, the availability of molecular nanotechnology will permit dramatic progress in human medical services. More than just an extension of molecular medicine, Nano medicine will help us understand how the biological machinery inside living cells operates at the Nano scale so that it can be employed in molecular machine systems to address complicated medical conditions such as cancer, AIDS, ageing and thereby bring about significant improvement and extension of natural human biological structure and function at the molecular scale.

Nano medical approaches to drug delivery centre on developing Nano scale particles or molecules to improve drug bioavailability that refers to the presence of drug molecules in the body part where they are actually needed and will probably do the most good. It is all about targeting the molecules and delivering drugs with cell precision.

The use of Nano robots in medicine would totally change the world of medicine once it is realized. For instance, by introducing these Nano robots into the body damages and infections can be detected and repaired. In short it holds that capability to change the traditional approach of treating diseases and naturally occurring conditions in the human beings.

1. Advanced therapies with reduced degree of invasiveness.

2. Reduced negative effects of drugs and surgical procedures.

3. Faster, smaller and highly sensitive diagnostic tools.

4. Cost effectiveness of medicines and disease management procedures as a whole.

5. Unsolved medical problems such as cancer, benefiting from the Nano medical approach.

6. Reduced mortality and morbidity rates and increased longevity in return.

1. Lack of proper knowledge about the effect of nanoparticles on biochemical pathways and processes of human body.

2. Scientists are primarily concerned about the toxicity, characterization and exposure pathways associated with Nano medicine that might pose a serious threat to the human beings and environment.

3. The societys ethical use of Nano medicine beyond the concerned safety issues, poses a serious question to the researchers.

Read more:

Nano Medicine: Meaning, Advantages and Disadvantages

What Might be the Best Way to Delivery Nanoparticle Therapy for Cancer? – Genetic Engineering & Biotechnology News

Scientists in the cancer nanomedicine community debate whether use of nanoparticles can best deliver drug therapy to tumors passively, allowing the nanoparticles to diffuse into tumors and become held in place, or actively, adding a targeted anti-cancer molecule to bind to specific cancer cell receptors and, in theory, keep the nanoparticle in the tumor longer. Now, new research on human and mouse tumors in mice by investigators at the Johns Hopkins Kimmel Cancer Center suggests the question is even more complicated.

Laboratory studies testing both methods in six models of breast cancer; five human cancer cell lines and one mouse cancer in mice with three variants of the immune system found that nanoparticles coated with trastuzumab, a drug that targets human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells, were better retained in the tumors than plain nanoparticles, even in tumors that did not express the pro-growth HER2 protein. However, immune cells of the host exposed to nanoparticles induced an anti-cancer immune response by activating T cells that invaded and slowed tumor growth. The results of the work Nanoparticle interactions with immune cells dominate tumor retention and induce T cellmediated tumor suppression in models of breast cancer, appears in Science Advances.

The factors that influence nanoparticle fate in vivo following systemic delivery remain an area of intense interest. Of particular interest is whether labeling with a cancer-specific antibody ligand (active targeting) is superior to its unlabeled counterpart (passive targeting). Using models of breast cancer in three immune variants of mice, we demonstrate that intratumor retention of antibody-labeled nanoparticles was determined by tumor-associated dendritic cells, neutrophils, monocytes, and macrophages and not by antibody-antigen interactions, write the investigators.

Systemic exposure to either nanoparticle type induced an immune response leading to CD8+ T cell infiltration and tumor growth delay that was independent of antibody therapeutic activity. These results suggest that antitumor immune responses can be induced by systemic exposure to nanoparticles without requiring a therapeutic payload. We conclude that immune status of the host and microenvironment of solid tumors are critical variables for studies in cancer nanomedicine and that nanoparticle technology may harbor potential for cancer immunotherapy.

Its been known for a long time that nanoparticles, when injected into the bloodstream, are picked up by scavenger-like macrophages and other immune system cells, explains senior study author Robert Ivkov, PhD, associate professor of radiation oncology and molecular radiation sciences at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Many researchers in the field have been focused on trying to reduce interactions with immune cells, because they have been trying to increase the circulation time of the nanoparticles and their retention in tumor cells. But our study demonstrates that the immune cells in the tumor collect and react to the particles in such a way to stimulate an anti-cancer response. This may hold potential for advancing beyond drug delivery toward developing cancer immunotherapies.

The investigators conducted a few in vitro experiments in their study. First, they applied some plain starch-coated iron oxide nanoparticles and others coated with trastuzumab to five human breast cancer cell lines, finding that the amount of binding between the trastuzumab-coated nanoparticles and cells depended on how much the cancer cells expressed the oncogene HER2. In people, HER2-positive breast cancers are among the most resistant to standard chemotherapy.

Trastuzumab, sold under the name Herceptin, targets the HER2-positive tumor cells and triggers the immune system as well.

Responses were surprisingly different in animal models, the researchers report. In separate experiments, the team used the nanoparticles in two immune-deficient strains of mice engrafted with cells from five human breast cancer cell linestwo that were HER2 negative and three that were HER2 positive. When they studied the animals tumors 24 hours later, they noticed that nanoparticles coated with trastuzumab were found in a concentration two to five times greater than the plain nanoparticles in all types of tumors, regardless of whether they expressed the HER2 protein. They also found that the number of trastuzumab-coated nanoparticles was even greater (tenfold) in mice that had a fully functional immune system and were bearing mouse-derived tumors.

This led the researchers to suspect that the host animals immune systems were interacting strongly with the nanoparticles and playing a role in determining retention of the particles in the tumor, whether or not a drug was added.

More experiments, the team reports, revealed that tumor-associated immune cells were responsible for collecting the nanoparticles, and that mice bred with an intact immune system retained more of the trastuzumab-coated nanoparticles than mice bred without a fully functioning immune system.

In addition, inflammatory immune cells in the tumors immediate surroundings, or microenvironment, seized more of the coated nanoparticles than the plain ones. Finally, in a series of 30-day experiments, the researchers found that exposure to nanoparticles inhibited tumor growth three to five times more than controls, and increased CD8-positive cancer-killing T cells in the tumors.

Surprisingly, Ivkov notes, the anti-cancer immune activating response was equally effective with exposure to either plain or trastuzumab-coated nanoparticles. Mice with defective T cells did not show tumor growth inhibition. The investigators say this demonstrated that systemic exposure to nanoparticles can cause a systemic host immune response that leads to anti-cancer immune stimulation and does not require nanoparticles to be inside the tumors.

Overall, our work suggests that complex interdependencies exist between the host and tumor immune responses to nanoparticle exposure, Ivkov says. These results offer intriguing possibilities for exploring nanoparticle targeting of the tumor immune microenvironment. They also demonstrate exciting new potential to develop nanoparticles as platforms for cancer immune therapies.

The investigators say they also plan to study whether the same types of immune responses can be generated for noncancer conditions, such as infectious diseases.

More here:

What Might be the Best Way to Delivery Nanoparticle Therapy for Cancer? - Genetic Engineering & Biotechnology News

Nano Healthcare Technology For Medical Equipment Market Business Opportunities, 2020 Trends, Challenges and Standardization, Research, Key Players and…

Global Nano Healthcare Technology For Medical Equipment MarketThis research report provides detailed study accumulated to offer Latest insights about acute features of the Nano Healthcare Technology For Medical Equipment Market. The report contains different market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary and SWOT analysis.It presents the 360-degree overview of the competitive landscape of the industries. Nano Healthcare Technology For Medical Equipment Market is showing steady growthand CAGR is expected to improve during the forecast period.

Manufacturer DetailSmith & NephewStrykerThermo Fisher Scientific3MGEMerckAbbottAstraZenecaFerroPerkinElmer

Product Type SegmentationBiochipsImplantable MaterialsMedical Textile and Wound DressingActive Implantable Devices

Industry SegmentationTherapeutic ApplicationsDiagnostics ApplicationsResearch Applications

Global Nano Healthcare Technology For Medical Equipment Market report provides you with detailed insights, industry knowledge, market forecasts and analytics. The report on the global Nano Healthcare Technology For Medical Equipment industry also clarifies economic risks and environmental compliance. Global Nano Healthcare Technology For Medical Equipment market report assists industry enthusiasts including investors and decision makers to make confident capital investments, develop strategies, optimize their business portfolio, innovate successfully and perform safely and sustainably.

Nano Healthcare Technology For Medical Equipment Market: Regional Analysis Includes:

Major Points Covered in TOC:

Key Questions Answered in the Report Include:

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

About Us:

Qurate Business Intelligence delivers unique market research solutions to its customers and help them to get equipped with refined information and market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Contact Us:Web:www.qurateresearch.comE-mail:[emailprotected]Ph: US +13393375221, IN +919881074592

Link:

Nano Healthcare Technology For Medical Equipment Market Business Opportunities, 2020 Trends, Challenges and Standardization, Research, Key Players and...

Global Healthcare Nanotechnology Market 2019 Present Status and Future Opportunities by Major Companies Typs and Applications 2024 – The Fuel Fox

The report on the Global Healthcare Nanotechnology Market has been prepared after conducting a comprehensive research through a systematized methodology. These skills are useful for scrutinizing the market on the terms of outlined research guidelines. Mainly, global Healthcare Nanotechnology market research report covers all the information about the target audience, manufactures, vendors, research papers, products and many more.

Request a sample of this report @ https://www.orbispharmareports.com/sample-request/13705

Keeping a focus on the overall market aspects, and perceptions, this report vastly covers profiles of the companies who have made it big in this particular field along with their sales data and other data. It also suggests the business models, innovations, growth and every information about the big manufacturers that will be present the future market estimates. Every market consists of set of manufacturers, vendors and consumers that gives a definition to the market, its each and every move, achievements. All these are the important subjects required to study the analysis of the global Healthcare Nanotechnology market. It also includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure. In addition, this report offers significant data through the SWOT analysis, investment return data, and investment feasibility analysis.

Top Companies Analysis:

AmgenTeva PharmaceuticalsAbbottUCBRocheCelgeneSanofiMerck & CoBiogenStrykerGilead SciencesPfizer3M CompanyJohnson & JohnsonSmith & NephewLeadiant BiosciencesKyowa Hakko KirinShireIpsenEndo International

Browse the complete report @ https://www.orbispharmareports.com/global-healthcare-nanotechnology-market-2019-present-status-and-future-opportunities-by-major-companies-typs-and-applications-2024/

The global Healthcare Nanotechnology market report also features a comprehensive quantitative and qualitative evaluation by analysing information collected from market experts and industry participants in the major points of the market value chain. The data offered in global Healthcare Nanotechnology market report is gathered based on the latest industry news, trends, as well as opportunities. This study offers a separate analysis of the major trends in the existing market, mandates and regulations, micro & macroeconomic indicators is also comprised in this report. By doing so, the study estimated the attractiveness of every major segment during the prediction period.

Segmentation by Type:

NanomedicineNano Medical DevicesOther

Segmentation by Application:

AnticancerCNS ProductAnti-infectiveOther

Moreover, the report comprises the analysis of opportunities available in the Healthcare Nanotechnology market on the global level. It also includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure.The annual progression for the global Healthcare Nanotechnology market in different regions cannot always be listed down as it will keep changing, thus studying and reviewing markets occasionally becomes vital. In addition, the Healthcare Nanotechnology market report provides a detailed information about the key market players along with the strategies they implemented to gain market existence and develop themselves. The report includes precise market estimations depending on current market status and future market forecasts.

Make an enquiry of this report @ https://www.orbispharmareports.com/enquiry-before-buying/13705

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

See original here:

Global Healthcare Nanotechnology Market 2019 Present Status and Future Opportunities by Major Companies Typs and Applications 2024 - The Fuel Fox

Nanobiotix 2019 Q4 and Annual Revenues – BioSpace

NANOBIOTIX (Paris:NANO) (Euronext : NANO ISIN : FR0011341205 the Company), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited annual revenues for Q4 and the unaudited revenues for the year ended December 31, 2019.

2019 Revenues

In K

Twelve months Ended

December 31st, 2019

Twelve months Ended

December 31st, 2018

Revenues

68

105

Of which licenses

-

-

Of which services

68

99

Other sales

-

6

Revenue for Q4 2019

In K

Q4 2019

Q3 2019

Q2 2019

Q1 2019

Revenues

20

11

32

5

Of which licenses

-

-

-

-

Of which services

20

11

32

5

Activity and results

Nanobiotixs revenue for the fourth quarter amounted to approximatively 20k.

Most of the revenues generated by the Company during this period result from the recharge of costs related to our license and collaboration agreement with PharmaEngine.

Overall, Nanobiotixs annual revenue in 2019 amounted to approximatively 68k.

The amount of cash and cash equivalent as of December 31st, 2019 amounted to 35 094k. This amount does not include the research tax credit related to 2018, normally expected in Q4 which was received in February 2020.

In November 2019, Nanobiotix announced promising results from a pre-clinical immuno-oncology study of NBTXR3 at the 2019 Annual Meeting of the Society for Immunotherapy of Cancer (SITC). In the study, conducted at The University of Texas MD Anderson Cancer Center, researchers studied NBTXR3 activated by radiation therapy in combination with anti-PD-1 treatment in immunocompetent mice. Combination treatment that included NBTXR3 and anti-PD-1 increased local control of the irradiated tumor, generated a marked abscopal effect, decreased the number of spontaneous lung metastases, and significantly increased survival when compared to other treatments in the study, including anti-PD-1 combined with radiation therapy alone. The results indicated that the combination treatment has the potential to achieve an equivalent abscopal effect at a lower dose of radiation.

The study also included an in vivo RadScopal model in which a second tumor received a low dose of radiation while the first tumor received a full dose. In this model, researchers evaluated NBTXR3 activated by radiation therapy combined with anti-PD-1 and anti-CTLA-4 treatment. In the study, combination treatment triggered better local control, along with significant increases in abscopal effect and survival, when compared to all other tested combinations. Several complete responses were observed in the second tumor of the group that received the NBTXR3 combination, while none were observed in the other groups. Nanobiotix believes these results could pave the way for the use of NBTXR3 to improve treatment outcomes for immunooncology patients, including checkpoint inhibitor non-responders.

On December 16th 2019, Nanobiotix received the French 2019 Prix Galien award for Most Innovative MedTech. This award recognizes outstanding biomedical and medical technology product achievements that improve the human condition.

2020 Financial agenda

Nanobiotix plans to announce its financial and operating results as follows:

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. The Company also possesses an affiliate, Curadigm, located in Paris, France and Cambridge, MA in the U.S.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005446/en/

Read more from the original source:

Nanobiotix 2019 Q4 and Annual Revenues - BioSpace

Dying Of Flu, College Student Used Cellphone To Call 911. He Died When Police Couldn’t Find His Location. – Kaiser Health News

Location technology is "kind of a coin toss." The FCC has given carriers until 2021 to make sure transmission locations are within 50 yards 80% of the time. Public health news is on USPS work-related injuries, a biomedical research contest, suicide-crisis centers, prostate cancer, a lucky fall, perinatal stroke, birthing plans, disparity in birth outcomes, medical clowns, chocolate's appeal, friendship and health, childhood prosthetics, and healthy beverages, as well.

The Washington Post:College Student Yeming Shen Died Of Flu In Troy, N.Y., After 911 Couldnt Track His Location.Yeming Shen called 911 on Feb. 10. He was alone in his Troy, N.Y., apartment, dying of the flu. But the garbled call was unintelligible to the operators, and police couldnt pinpoint the phones location. For 45 minutes after Shen called 911, five police officers, three firefighters and a police dog searched in vain for the student. All they had was a general area encompassing two apartment buildings. They eventually gave up without finding Shen. Six hours later, the Rensselaer Polytechnic Institute students roommate discovered his body, the Times Union first reported. (Kornfield, 2/22)

ProPublica:The Postal Service Fired Thousands Of Workers For Getting Injured While Delivering And Processing Your MailOne night in 2009, Madelaine Sattlefield lifted an 80-pound tray of letters carefully sorted by Missouri ZIP code. She had done this task thousands of times in nine years, but on this night, her arm seared with pain and went limp by her side. The tray crashed and sent envelopes cascading around her. She could barely move but immediately worried about what an injury might mean for her job. Anxiety had kicked in. I was like, what are they going to say, what are they going to do? Sattlefield said. (Jameel, 2/24)

Stat:Here Are The Contenders For STAT Madness 2020ADNA microscope. A gene therapy for bubble boy disease. The restoration of cellular activity in pig brains four hours after death. Nano-robots that might clean teeth better than flossing. These are just some of the 64 important discoveries and inventions included in this years STAT Madness, a bracket-style competition to honor the best biomedical research published in 2019. (2/24)

Stateline:As Suicide Rates Climb, Crisis Centers ExpandNationwide, most people picked up by police for a misdemeanor while in a psychiatric crisis are taken directly to a hospital emergency department, where they typically are held for hours or days, often involuntarily confined, according to emergency department surveys. Many are charged and held in jail with no mental health professional to talk to and no access to psychiatric medicines. The same goes for people with drug addiction. In the past five years, thats become a rarity in Arizona. As in other parts of the country, Arizonas crisis centers are open 24 hours, seven days a week, and everyone is accepted, regardless of whether they have health insurance. (Vestal, 2/24)

The New York Times:Debating The Value Of PSA Prostate ScreeningWeve long been schooled on the lifesaving value of early detection of a potentially deadly cancer. So when a simple blood test was introduced in 1994 that could detect the possible presence of prostate cancer, the second leading cause of cancer deaths among American men, its not hard to understand why it quickly became hugely popular. (Brody, 2/24)

The Washington Post:Synovial Chondromatosis: A Hard Fall Unmasked This Unusual And Painful ConditionIf she hadnt tripped over her neighbors dog, causing her to miss the step down into a sunken living room where she landed squarely on her left hip, Lynda Holland still might not know what was wrong. Holland scrambled to her feet, shaken and grateful she hadnt been injured: Her puffy down coat had cushioned her fall onto the hardwood floor. Then she realized the pain that had dominated her life for the previous six years had suddenly diminished. (Boodman, 2/22)

The Washington Post:Perinatal Stroke: Some Infants In Utero Lose Blood Supply To Their Brains, Causing Physical Or Cognitive Problems Later. New Therapies May Help.Nicole Dodds first noticed her son, Rowan, was having trouble using the right side of his body when he was about 6 months old. Babies typically use both hands to pick up toys and lift their chest off the floor at that age, but Rowan was mostly using his left arm and hand, keeping his right hand balled in a fist. That started a string of doctor visits. Around Rowans first birthday, doctors did an MRI and diagnosed his one-sided weakness as hemiplegia, probably caused by a stroke he sustained in utero. This surprised Dodds, since as far as she knew shed had a totally normal pregnancy and birth. (Witman, 2/22)

NBC News:She Wanted A 'Freebirth' With No Doctors. Online Groups Convinced Her It Would Be OK.For women who havent gone into labor by 42 weeks, just about every medical and birth professional recommends induction a jump-start to labor from medicines that ripen the cervix or contract the uterus. But Judith, an artist and freethinker who believes in all that hippy jazz, had a different kind of birth plan one that dismissed medical recommendations and relied on nature and intuition, that rejected a sterile hospital for a warm pool in her own home and that avoided doctors and midwives. Instead, Judith wanted to be with only her husband and her closest friend, a plan known as freebirth, or unassisted birth, by the tiny subculture of women who practice it. (Zadrozny, 2/21)

GMA:Stunning Photos Of Black Women Raises Awareness About Disparity In Birth OutcomesIt was about five years ago when Dallas-Fort Worth photographer Elaine Baca photographed her first birth. Until then, she had been primarily working weddings... According to the Centers for Disease Control and Prevention, the risk of pregnancy-related deaths for black women is 3 to 4 times higher than those of white women."It's important for people to see and understand that black women and babies who are dying in childbirth are not just statistics put out by the CDC," Baca told "GMA." (Brown, 2/24)

The Washington Post:Clowns Can Help Treatment In HospitalsMedicine is serious business. But for a growing number of patients, a trip to the hospital may include a laugh with a clown. Medical clowns health-care workers who dress up and act like clowns to help make medical procedures and hospital stays less stressful can be found around the world. The growing field relies on the age-old performance art of clowning to help lift the strain that can pervade the treatment of all-too-serious health concerns. (Blakemore, 2/22)

NBC News:Why Chocolate Is So Addicting And How To Tap Into The Health BenefitsThough chocolate is typically divided into three categories: dark, milk and white, the latter two really should just be called highly-processed interpretations of chocolate, because thats basically what they are. And its the processed sugars, salts and fats that make these varieties so tasty which is also what makes them so addictive. (Spector, 2/23)

CNN:Want To Lose More Weight? Intensive Therapy From Dietitians Can Help Older Adults, Study FindsOlder adults may have better success at losing weight if they do it with the help of intensive behavioral therapy from dietitians, a new study suggests. Intensive behavioral therapy for obesity, or IBTO, is a customized treatment that helps people change their eating and exercise behaviors through a series of one-on-one counseling sessions. (Rogers, 2/21)

NPR:How Good Friends Are Good For Your HealthLydia Denworth wants you to make more time for your friends. We don't fully appreciate our friendships, says the science writer and author of the new book Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond. If we did, we'd take cultivating those intimate bonds as seriously as working out or eating well. Because, she writes, a new field of science is revealing that social connections play a vital role in our health. (Renken, 2/22)

The Washington Post:Children Who Need Prosthetics Can Quickly Outgrow Them And Insurers Are Reluctant To Pay For Running Legs. Nonprofits Are Helping Out.Faith Trznadel was born without a tibia bone, and when she was 10months old, doctors had to amputate her lower leg. The hardest part is the staring, the snickering, said Faiths mother, Sheila Trznadel, about how other people treated her daughter. One message to get across to people is its okay to ask questions. ... Its better to ask questions than just stare. [Its] getting rid of that stigma. (Furby, 2/23)

The New York Times:Milk And Juice Are Not As Needed As You Might ThinkIs there such a thing as a healthful beverage? In truth, theres not much of a health case to drink any beverage other than water after the age of 2 despite the marketing and advertising you might have seen on the benefits of things like dairy milk, plant-based milks, juices and more. (Carroll, 2/24)

More here:

Dying Of Flu, College Student Used Cellphone To Call 911. He Died When Police Couldn't Find His Location. - Kaiser Health News

Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form N | IJN – Dove Medical Press

Xiaoyi Zhang, 1, 2 Yixin Zhang, 1, 2 Yaonan Wang, 1, 2 Jianhui Wu, 1, 2 Haiyan Chen, 1, 2 Ming Zhao, 13 Shiqi Peng 1, 2

1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, Peoples Republic of China; 2Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, Peoples Republic of China; 3Beijing Laboratory of Biomedical Materials and Key Laboratory of Biomedical Materials of Natural Macromolecules, Department of Biomaterials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100026, Peoples Republic of China

Correspondence: Shiqi Peng; Ming ZhaoDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, No. 10, Youanmenwaixitoutiao, Fengtai District, Beijing 100069, Peoples Republic of ChinaTel +86 10 8391 1528; +86 10 8391 1535Fax +86 10 8391 1528; +86 10 8391 1533Email sqpeng@bjmu.edu.cn; maozhao@126.com

Background: 1-(4-isopropylphenyl)--carboline-3-carboxylic acid (ICCA) was modified by Trp-Phe-Phe to form 1-(4-isopropylphenyl)--carboline-3-carbonyl-Trp-Phe-Phe (ICCA-WFF).Purpose: The object of preparing ICCA-WFF was to enhance the in vivo efficacy of ICCA, to explore the possible targeting action, and to visualize the nano-feature.Methods: The advantages of ICCA-WFF over ICCA were demonstrated by a series of in vivo assays, such as anti-tumor assay, anti-arterial thrombosis assay, anti-venous thrombosis assay, P-selectin expression assay, and GPIIb/IIIa expression assay. The nano-features of ICCA-WFF were visualized by TEM, SEM and AFM images. The thrombus targeting and tumor-targeting actions were evidenced by FT-MS spectrum analysis.Results: The minimal effective dose of ICCA-WFF slowing tumor growth and inhibiting thrombosis was 10-fold lower than that of ICCA. ICCA-WFF, but not ICCA, formed nano-particles capable of safe delivery in blood circulation. In vivo ICCA-WFF, but not ICCA, can target thrombus and tumor. In thrombus and tumor, ICCA-WFF released Trp-Phe-Phe and/or ICCA.Conclusion: Modifying ICCA with Trp-Phe-Phe successfully enhanced the anti-tumor activity, improved the anti-thrombotic action, formed nano-particles, targeted tumor tissue and thrombus, and provided an oligopeptide modification strategy for heterocyclic compounds.

Keywords: ICCA, modification, Trp-Phe-Phe, anti-tumor, thrombus targeting, release, toxicity, nano-species

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

The rest is here:

Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form N | IJN - Dove Medical Press